Home > Q-Med Launches a Pharmaceutical in Sweden
Q-Med Launches a Pharmaceutical in Sweden
By: Business News Q-Med (Nasdaq:QMED) (STO:QMED) hereby announces that a pharmaceutical, Cosmofer(R) (low molecular iron dextran), has now been approved for sales in Sweden. It is estimated that sales will start towards the end of the year.
Q-Med has an agreement with the Danish manufacturer Nebo/Pharmacosmos (www.pharmacosmos.com) concerning sales rights for the preparation on the Swedish market.
|
|
|
Cosmofer is given through an infusion in a vein or as an injection in a muscle. What is unique for Cosmofer is that the patient's total need can be given in a single dose. The product is used for the treatment of serious iron deficiency where treatment with tablets is not tolerated or does not have sufficient effect. The need can be seen above all in people with kidney disease, in cancer patients, in cases of inflammatory intestinal disease, during pregnancy and in connection with surgical procedures when it is desirable to avoid blood transfusions.
Q-Med has previous experience of intravenous iron and had sales of a similar preparation up until 1999.
|
WHO estimates that approximately 3 billion people, more than 30% of the world's population, have anemia, above all due to iron deficiency. In Sweden there are 4 oral iron products, which together have sales of SEK 28.5 million. Only one intravenous product exists today, Venofer, with sales of SEK 26.6 million during 2005.
In the US, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.
Q-Med is a rapidly growing and profitable biotechnology/medical device company. The company develops, produces, markets and sells implants for esthetic and medical use. All products are based on the company's patented technology for the production of stabilized non-animal hyaluronic acid, NASHA(TM). The product portfolio today contains: RESTYLANE, for the filling out of lips and facial wrinkles and for facial contouring; DUROLANE, for the treatment of osteoarthritis of the hip and knee joints; DEFLUX, for the treatment of vesicoureteral reflux (a malformation of the urinary bladder) in children and ZUIDEX, for the treatment of stress urinary incontinence in women. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 560 co-workers, with approximately 370 at the company's head office and production facility in Uppsala, Sweden. The Q-Med share is listed on the O-list of the Stockholm Stock Exchange. www.q-med.com
NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX and all product names within the RESTYLANE family are trademarks that belong to Q-Med. |